Candel Therapeutics, Inc. (CADL)
Chart Events
Performance Outlook
| Previous Close | 4.0000 |
| Open | 4.0000 |
| Bid | 3.8800 x 800 |
| Ask | 4.1500 x 2200 |
| Day's Range | 3.9650 - 3.9700 |
| 52 Week Range | 3.3300 - 14.7800 |
| Volume | |
| Avg. Volume | 57,351 |
| Market Cap | 113.769M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9140 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CADL
Related Research
- Candel Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 07/30/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat10 months agoArgus Research
- GlobeNewswire
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwright’s upcoming Annual Global Investment Conference. Format: Pre-recorded corporate presentationDate/Time: May 24, 2022, on-demand viewing starts at 7:00 am ET To
- GlobeNewswire
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Cash position bolstered through debt financing to support operations into the fourth quarter of 2023NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “2022 is off to a great start as we continue to a
- GlobeNewswire
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, which will be held in person from June 3 – 7, 2022, at the McCormick Place Convention Center in Chicago, Illinois. The presented data will detail clinical outc
